Acorda Therapeutics
15 Skyline Drive
Hawthorne
New York
10532
United States
Tel: 914-347-4300
Fax: 914-347-4560
Website: http://www.acorda.com/
Email: acorda@acorda.com
About Acorda Therapeutics
Acorda Therapeutics is a privately held biotechnology company developing therapies for spinal cord injury (SCI) and related neurological conditions, including multiple sclerosis (MS). The Company's lead product, Fampridine-SR, is in Phase 3 clinical trials for chronic SCI and Phase 2 for MS.Fampridine-SR acts to combat the effects of demyelination in the spinal cord. Myelin is the insulating sheath around nerve processes; when it is damaged due to trauma or disease, electrical impulses from the brain cannot be conducted past the demyelinated area. Fampridine-SR chemically blocks the exposed voltage-gated potassium channels, allowing the impulse from the brain to be conducted more normally past the area of damage. Fampridine is being studied in Phase 3 clinical trials to evaluate its efficacy in reducing spasticity in people with chronic spinal cord injury. Secondary endpoints in the study include evaluating its effect on bladder, bowel, and sexual function. The Company is also conducting a 152 patient, late Phase 2 clinical study in MS to evaluate Fampridine-SR's efficacy in walking speed and muscle strength.
Acorda's technology platform also includes two remyelinating agents in preclinical development for MS. The first is M1, a class of human monoclonal antibodies that have been shown to remyelinate the central nervous system in animal models, and the second is GGF2, a product of the neuregulin 1 gene. Preclinical studies have shown that GGF2 can stimulate the cell growth necessary to protect and regenerate damaged myelin. Additionally, Acorda is developing protein- and stem cell-based technologies for regeneration and repair of the spinal cord and brain.
In 2002, Acorda was the recipient of the National Spinal Cord Injury Association's L. W. Freeman Award for scientific research.
Key Management:
Ron Cohen, M.D., President and CEO Andrew R. Blight, Ph.D., Executive Vice President, Research & Development Mary Fisher, Vice President, Marketing and Strategic Planning Elliott A. Gruskin, Ph.D., Vice President, Research & Development Mitchell Katz, Ph.D., Vice President, Clinical Programs David Lawrence, Vice President, Finance Mark R. E. Pinney, C.F.A., Chief Financial Officer and Director Harold Safferstein, Ph.D., J.D., Vice President, Business Development
Last Updated: 05-09-03
598 articles about Acorda Therapeutics
-
Acorda Therapeutics Chief Scientific Officer Andrew R. Blight Receives Purchase College Science Entrepreneurship Award
4/26/2010
-
Acorda Therapeutics to Host Conference Call to Report First Quarter 2010 Financial Results on April 30, 2010
4/23/2010
-
Acorda Therapeutics Announces Data on AMPYRA(TM) (dalfampridine) Presented at American Academy of Neurology Meeting
4/13/2010
-
Acorda Therapeutics Announces Filing of Patent Extension Applications for AMPYRA(TM) (dalfampridine)
3/22/2010
-
Acorda Therapeutics to Present at the Cowen and Company 30th Annual Health Care Conference
3/2/2010
-
Acorda Therapeutics Announces Availability of AMPYRA(TM) (dalfampridine)
3/1/2010
-
Acorda Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results
2/23/2010
-
Acorda Therapeutics Announces Adrian L. Rabinowicz Joins as Senior Vice President of Medical Affairs
2/22/2010
-
Acorda Therapeutics to Host Conference Call to Report Fourth Quarter and Full Year 2009 Financial Results on February 23, 2010
2/17/2010
-
Regis Technologies, Inc. Passes FDA Pre-Approval Inspection for Acorda Therapeutics' Approved Multiple Sclerosis Drug, Ampyra(TM)
1/28/2010
-
US FDA Approves Acorda Therapeutics MS Drug to Help with Walking
1/25/2010
-
Acorda Therapeutics Announces Lauren Sabella Joins as Executive Vice President of Commercial Development
1/25/2010
-
Acorda Therapeutics to Present at the 28th Annual JPMorgan Healthcare Conference
1/4/2010
-
Acorda Therapeutics to Present at the 2009 Deutsche Bank Biotech Boston Confab
12/8/2009
-
Acorda Therapeutics to Present at the 21st Annual Piper Jaffray Health Care Conference
11/24/2009
-
Acorda Therapeutics to Present at the Lazard Capital Markets 6th Annual Healthcare Conference
11/16/2009
-
Acorda Therapeutics Reports Third Quarter 2009 Financial Results
11/3/2009
-
Acorda Therapeutics to Host Conference Call to Report Third Quarter 2009 Financial Results on November 3, 2009
10/27/2009
-
Acorda Therapeutics (<a href="http://www.biospace.com/jobListingCompany.aspx?JOB_CUSTOMER_ENTITY_ID=396566&source=newsjo blink">JOBS) Announces Extension of Fampridine-SR PDUFA Goal Date to January 22, 2010
10/23/2009
-
Acorda Therapeutics (JOBS) Announces Positive Vote by FDA Advisory Committee for Fampridine-SR
10/15/2009